Click on headlines below to download research

Moving ahead on all fronts
SymBio Pharmaceuticals | 27/02/2017

During 2017 we expect updates on all three of SymBio’s main assets. We expect Treakisym sales growth via partner Eisai following approvals during…

Moving ahead on all fronts
SymBio Pharmaceuticals | 27/02/2017

During 2017 we expect updates on all three of SymBio’s main assets. We expect Treakisym sales growth via partner Eisai following approvals during…

Treakisym approvals should lead to sales uplift
SymBio Pharmaceuticals | 06/01/2017

SymBio recently obtained approvals for Treakisym in Japan in the additional indications of first-line low grade non-Hodgkin’s lymphoma (NHL) and…